Raymond James targets Addus HomeCare stock at USD 137.00

Published on 10/02/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 8.00 percent to USD 377.41 million. Addus HomeCare stock costs EUR 100.25 on October 2, 2026 versus EUR 99.25.

ADUS, US0067391062, Illustration mit AI erstellt.

Addus HomeCare (ISIN US0067391062) was trading at EUR 100.25 at Lang & Schwarz on October 2, 2026 at 3:01 p.m. CEST, up 1.01 percent versus the prior close of EUR 99.25. On September 28, 2026, Raymond James initiated coverage with an Outperform rating and a USD 137.00 price target, as Investing.com reported.

Revenue growth meets analyst scrutiny

Addus reported second-quarter 2026 revenue of USD 377.41 million, an 8.00 percent year-over-year increase, according to MarketBeat. Adjusted earnings per share came to USD 1.73 against consensus of USD 1.70, a USD 0.03 upside comparison for the quarter.

The company operates across personal care, hospice and home health services. Its second-quarter GAAP net income was USD 27.61 million, while operating cash flow reached USD 40.01 million, giving the results a cash-generation dimension beyond the adjusted earnings figure.

Targets diverge after the deal

Raymond James placed its USD 137.00 target 22.65 percent above the USD 111.70 Nasdaq price used in the comparison on October 1, 2026. The target reflects the analyst view that home-based care demand and acquisitions can support growth.

The counterpoint came from BofA Securities. MarketScreener reported on September 16, 2026, that BofA cut its target from USD 140.00 to USD 125.00 and moved its rating from Buy to Neutral, citing slower organic growth.

Stock remains below its yearly high

The Nasdaq quote was last at USD 111.70 on October 1, 2026 at 4:00 p.m. ET, within a 52-week range of USD 87.95 to USD 124.44. That leaves the primary-exchange price 10.25 percent below the yearly high, while the Lang & Schwarz euro quote gained 1.01 percent against its own prior close.

For investors, the central tension is clear: second-quarter revenue growth and a modest earnings comparison support the expansion case, while the BofA target cut highlights execution and organic-growth risks.